About 4575

Founded: 2000
Employees: 14
CEO: Takumi Kawabe
WebsiteView website: www.canbas.co.jp

CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.

Recent 4575 News & Updates

New Risk • Mar 03

New minor risk - Market cap size

The company's market capitalization is less than US$100m. Market cap: JP¥14.7b (US$93.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥14.7b market cap, or US$93.3m).

Recent updates

No updates

CanBas Co., Ltd. Stock Price

4575 Share Price Performance

4575 Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

CanBas Co., Ltd. Key Details

About 4575

Recent 4575 News & Updates

CanBas Co., Ltd. to Report Fiscal Year 2026 Results on Aug 12, 2026

Is CanBas (TSE:4575) In A Good Position To Deliver On Growth Plans?

New minor risk - Market cap size

Recent updates

CanBas Co., Ltd. Competitors

Chugai Pharmaceutical

Takeda Pharmaceutical

Otsuka Holdings

Daiichi Sankyo Company